Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3- piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5663-5679

  Heerding, Dirk A ^a   Rhodes, Nelson ^a   Leber, Jack D ^a   Clark, Tammy J ^a,b   Keenan, Richard M ^a   Lafrance, Louis V ^a   Li, Mei ^a   Safonov, Igor G ^a   Takata, Dennis T ^a   Venslavsky, Joseph W ^a   Yamashita, Dennis S ^a   Choudhry, Anthony E ^a   Copeland, Robert A ^a   Lai, Zhihong ^a   Schaber, Michael D ^a   Tummino, Peter J ^a   Strum, Susan L ^a   Wood, Edgar R ^a   Duckett, Derek R ^a,c   Eberwein, Derek ^a   Knick, Victoria B ^a   Lansing, Timothy J ^a   McConnell, Randy T ^a   Zhang, ShuYun ^a   Minthorn, Elisabeth A ^a   Concha, Nestor O ^a   Warren, Gregory L ^a   Kumar, Rakesh ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b Dana College   (United States)

^c Scripps Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (4 AMINO 1,2,5 OXADIAZOL 3 YL) 1 ETHYL 7 [(3 PIPERIDINYLMETHYL)OXY] 1H IMIDAZO[4,5 C]PYRIDIN 4 YL] 2 METHYL 3 BUTYN 2 OL; GLYCOGEN SYNTHASE KINASE 3BETA; GSK 690693; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME INHIBITOR INTERACTION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IC 50; MOUSE; NONHUMAN; SCID MOUSE; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANIMALS; FEMALE; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICE; MICE, SCID; MODELS, MOLECULAR; OXADIAZOLES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; SUBSTRATE SPECIFICITY;

EID: 52449089445     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8004527     Document Type: Article

References (34)

1. Jetzt, A.; Howe, J. A.; Horn, M. T.; Maxwell, E.; Yin, Z.; Johnson, D.; Kumar, C. C. Adenoviral-Mediated Expression of a Kinase-Dead Mutant of Akt Induces Apoptosis Selectively in Tumor Cells and Suppresses Tumor Growth in Mice. Cancer Res. 2003, 63, 6697-6706.
2. Bellacosa, A.; Kumar, C. C.; Di Cristofano, A.; Testa, J. R. Activation of AKT Kinases in Cancer: Implications for Therapeutic Targeting. Adv. Cancer Res. 2005, 94, 29-86.
3. Barnett, S. F.; Bilodeau, M. T.; Lindsley, C. W. The Akt/PKB Family of Protein Kinases: A Review of Small Molecule Inhibitors and Progress towards Target Validation. Curr. Top. Med. Chem. 2005, 5, 109-125.
4. Altomare, D. A.; Testa, J. R. Perturbations of the AKT Signaling Pathway in Human Cancer. Oncogene 2005, 24, 7455-7464.
5. Dillon, R. L.; White, D. E.; Muller, W. J. The Phosphatidyl Inositol 3-Kinase Signaling Network: Implications for Human Breast Cancer. Oncogene 2007, 26, 1338-1345.
6. Chow, L. M. L.; Baker, S. J. PTEN Function in Normal and Neoplastic Growth. Cancer Lett. 2006, 241, 184-196.
7. Lindsley, C. W.; Barnett, S. F.; Yaroschak, M.; Bilodeau, M. T.; Layton, M. E. Recent Progress in the Development of ATP-Competitive and Allosteric Akt Kinase Inhibitors. Curr. Top. Med. Chem. 2007, 7, 1349-1363.
8. Li, Q. Recent Progress in the Discovery of Akt Inhibitors as Anticancer Agents. Expert Opin. Ther. Pat. 2007, 17, 1077-1130.
9. Heerding, D. A.; Safonov, I. G.; Verma, S. K. Small Molecule Inhibitors of AKT/PKB Kinase as a Strategy for Treating Cancer. Annu. Rep. Med. Chem. 2007, 42, 365-376.
10. Lin, X.; Murray, J. M.; Rico, A. C.; Wang, M. X.; Chu, D. T.; Zhou, Y.; Del Rosario, M.; Kaufman, S.; Ma, S.; Fang, E.; Crawford, K.; Jefferson, A. B. Discovery Oof 2-Pyrimidyl-5-Amidothiophenes as Potent Inhibitors for AKT: Synthesis and SAR Studies. Bioorg. Med. Chem. Lett. 2006, 16, 4163-4168.
11. Collins, I.; Caldwell, J.; Fonseca, T.; Donald, A.; Bavetsias, V.; Hunter, L.-J.K.; Garrett, M. D.; Rowlands, M. G.; Aherne, G. W.; Davies, T. G.; Berdini, V.; Woodhead, S. J.; Davies, D.; Seavers, L. C. A.; Wyatt, P. G.; Workman, P.; McDonald, E. Structure-Based Design of Isoquinoline-5-Sulfonamide Inhibitors of Protein Kinase B. Bioorg. Med. Chem. 2006, 14, 1255-1273.
12. Luo, Y.; Shoemaker, A. R.; Liu, X.; Woods, K. W.; Thomas, S. A.; de Jong, R.; Han, E. K.; Li, T.; Stoll, V. S.; Powlas, J. A.; Oleksijew, A.; Mitten, M. J.; Shi, Y.; Guan, R.; McGonigal, T. P.; Klinghofer, V.; Johnson, E. F.; Leverson, J. D.; Bouska, J. J.; Mamo, M.; Smith, R. A.; Gramling-Evans, E. E.; Zinker, B. A.; Mika, A. K.; Nguyen, P. T.; Oltersdorf, T.; Rosenberg, S. H.; Li, Q.; Giranda, V. L. Potent and Selective Inhibitors of Akt Kinases Slow the Progress of Tumors in Vivo. Mol. Cancer Ther. 2005, 4, 977-986.
13. Zhao, Z.; Leister, W. H.; Robinson, R. G.; Barnett, S. F.; Defeo-Jones, D.; Jones, R. E.; Hartman, G. D.; Huff, J. R.; Huber, H. E.; Duggan, M. E.; Lindsley, C. W. Discovery of 2,3,5-Trisubstituted Pyridine Derivatives as Potent Akt1 and Akt2 Dual Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 905-909.
14. Wood, E. R.; Truesdale, A. T.; McDonald, O. B.; Yuan, D.; Hassell, A.; Dickerson, A. H.; Ellis, B.; Pennisi, C.; Horne, E.; Lackey, K.; Alligood, K. J.; Rusnak, D. W.; Gilmer, T. M.; Shewchuk, L. A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib). Cancer Res. 2004, 64, 6652-6659.
15. Copeland, R. A.; Pompliano, D. L.; Meek, T. D. Drug-Target Residence Time and Its Implications for Lead Optimization. Nat. Rev. Drug Discovery 2006, 5, 730-739.
16. Rhodes, N.; Heerding, D. A.; Duckett, D. R.; Eberwein, D. J.; Knick, V. B.; Lansing, T. J.; McConnell, R. T.; Gilmer, T. M.; Zhang, S. Y.; Robell, K.; Kahana, J. A.; Geske, R. S.; Kleymenova, E. V.; Choudhry, A. E.; Lai, Z. V.; Leber, J. D.; Minthorn, E. A.; Strum, S. L.; Wood, E. R.; Huang, P. S.; Kumar, R. Characterization of an AKT Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity. Cancer Res. 2008, 68, 2366-2374.
17. Bailey, N.; Bamford, M. J.; Garland, S.; Goodman, K. B.; Cui, H; Hilfiker, M. A.; Lee, D.; Panchal, T. A.; Stavenger, R. A.; Wilson, D. M.; Witherington, J. WO2003080610 A1, 2003.
18. Bamford, M. A.; Bailey, N.; Davies, S.; Dean, D. K.; Francis, L.; Panchal, T. A.; Parr, C. A.; Sehmi, S.; Steadman, J. G.; Takle, A. K.; Townsend, J. T.; Wilson, D. M. (1H-Imidazo[4,5-C]pyridin-2-yl)-1,2,5- oxadiazol-3-ylamine Derivatives: Further Optimisation as Highly Potent and Selective MSK-1-Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3407-3411.
19. Bamford, M. J.; Alberti, M. J.; Bailey, N.; Davies, S.; Dean, D. K.; Gaiba, A.; Garland, S.; Harling, J. D.; Jung, D. K.; Panchal, T. A.; Parr, C. A.; Steadman, J. G.; Takle, A. K.; Townsend, T.; Wilson, D. M.; Witherington, J. (1H-Imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine Derivatives: A Novel Class of Potent MSK-1-Inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3402-3406.
20. Stavenger, R. A.; Cui, H.; Dowdell, S. E.; Franz, R. G.; Gaitanopoulos, D. E.; Goodman, K. B.; Hilfiker, M. A.; Ivy, R. L.; Leber, J. D.; Marino, J. P.; Oh, H.-J.; Viet, A. Q.; Xu, W.; Ye, G.; Zhang, D.; Zhao, Y.; Jolivette, L. J.; Head, M. S.; Semus, S. F.; Elkins, P. E.; Kirkpatrick, R. B.; Dul, E.; Khandekar, S. S.; Yi, T.; Jung, D. K.; Wright, L. L.; Smith, G. K.; Behm, D. J.; Doe, C. P.; Bentley, R.; Chen, Z. X.; Hu, E.; Lee, D. Discovery of Aminofurazan-azabenzimidazoles as Inhibitors of Rho-Kinase with High Kinase Selectivity and Antihypertensive Activity. J. Med. Chem. 2007, 50, 2-5.
21. Irani, R. J.; SantaLucia, J., Jr. The Synthesis of Anti-Fixed 3-Methyl-3-deaza-2′-deoxyadenosine and Other 3H-Imidazo[4,5- C]pyridine Analogs. Nucleosides, Nucleotides Nucleic Acids 2002, 21, 737-751.
22. Corbet, J. -P.; Mignani, G. Selected Patented Cross-Coupling Reaction Technologies. Chem. Rev. 2006, 106, 2651-2710.
23. Chinchilla, R.; Najera, C. The Sonogashira Reaction: A Booming Methodology in Synthetic Organic Chemistry. Chem. Rev. 2007, 107, 874-922.
24. Yang, J.; Cron, P.; Good, V. M.; Thompson, V.; Hemmings, B. A.; Barford, D. Crystal Structure of an Activated Akt/Protein Kinase B Ternary Complex with GSK3-Peptide and AMP-PNP. Nat. Struct. Biol. 2002, 9, 940-944.
25. For a excellent description of the various binding pockets available to protein kinase inhibitors, see the following: Liao, J.J.-L. Molecular Recognition of Protein Kinase Binding Pockets for Design of Potent and Selective Kinase Inhibitors. J. Med. Chem. 2007, 50, 409-424.
26. BT474 is a breast tumor line chosen because it has activated AKT1 and AKT2 by virtue of ErbB2 overexpression. See the following: Nicholson, K. M.; Streuli, C. H.; Anderson, N. G. Autocrine Signalling through Erbb Receptors Promotes Constitutive Activation of Protein Kinase B/Akt in Breast Cancer Cell Lines. Breast Cancer Res. Treat. 2003, 81, 117-128.
27. LNCaP is a prostate line chosen because it has consitutively activated AKT1. See the following: Nakatani, K.; Thompson, D. A.; Barthel, A.; Sakaue, H.; Liu, W.; Weigel, R. J.; Roth, R. A. Up-Regulation of Akt3 on Estrogen Receptor-Deficient Breast Cancers and Androgen-Independent Prostate Cancer Lines. J. Biol. Chem. 1999, 274, 21528-21532.
28. d) of 3g to each enzyme and can therefore be compared for selectivity against these kinases.
29. Dummler, B.; Hemmings, B. A. Physiological Roles of PKB/Akt Isoforms in Development and Disease. Biochem. Soc. Trans. 2007, 35, 231-235.
30. Rusnak, D. W.; Lackey, K.; Affleck, K.; Wood, E. R.; Alligood, K. J.; Rhodes, N.; Ketih, B. R.; Murray, D. M.; Knight, W. B.; Mullin, R. J.; Gilmer, T. M. The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/Erbb-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-Derived Cell Lines in Vitro and in Vivo. Mol. Cancer Ther. 2001, 1, 85-94.
31. Shults, M. D.; Janes, K. A.; Lauffenburger, D. A.; Imperiali, B. A Multiplexed Homogeneous Fluorescence-Based Assay for Protein Kinase Activity in Cell Lysates. Nat. Methods 2005, 2, 277-284.
32. Copeland, R. A. Evaluation of Enzyme Inhibitors in Drug Discovery. A Guide for Medicinal Chemists and Pharmacologists; John Wiley & Sons, Inc.: New York, 2005.
33. See Supporting Information.
34. The crystallographic data described have been deposited with the RSCB Protein Data Bank (PDB code for 3g: 3DOE).